The debate continues, but this time with cystatin-C measurements. Read the #TenTweetNephJC summary here!
This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.
This week, we will discuss the VALIANT study, pegcetacoplan in C3G and IC MPGN.
2025 was rich in successful stories. Here are the top 10 that impressed our audience.
This week, we will discuss whether less is more when it comes to discontinuing dialysis in patients with AKI and a chance to recover.
The debate continues, but this time with cystatin-C measurements. Read the #TenTweetNephJC summary here!
Welcome to #TenTweetNephJC tweetorial
— Nephrology Jrnl Club (@NephJC) September 13, 2022
✳️ 10 tweets to catch-up with #NephJC ✳️
Have you ever prescribed piperacillin-tazobactam? Or avoided it due to fear of causing AKI?
Read on to learn more about the ‘nephrotoxin’ versus ‘pseudonephrotoxin’ debate pic.twitter.com/ZKX1ElhZds